June 27, 2014
Alternate Contact: Rebecca Spitz, MSBI | 212-523-4044 | email@example.com
HIV and its transmission has long been associated with injecting drug use, where hypodermic syringes are used to administer illicit drugs. Now, a newly reported study by researchers affiliated with New York University’s Center for Drug Use and HIV Research (CDUHR) in the journal PLOS One, shows that HIV infection among heterosexual non-injecting drug users (no hypodermic syringe is used; drugs are taken orally or nasally) in New York City (NYC) has now surpassed HIV infection among persons who inject drugs.
The study, “HSV-2 Co-Infection as a Driver of HIV Transmission among Heterosexual Non-Injecting Drug Users in New York City,” was conducted among drug users entering the Mount Sinai Beth Israel drug treatment programs in NYC. The researchers found that HIV infection among non-injecting drug users doubled over the last two decades, from 7% infected in the late 1990s (n= 785) to 14% (n=1764) currently. During this same time-frame, HIV infection among persons who inject drugs fell to 10%.
The increased efficiency for transmitting HIV occurs even when persons with herpes simplex virus 2 (HSV-2) are between outbreaks, as herpes increases both susceptibility to and transmissibility of HIV. More than half of the non-injecting drug users in the study were infected with HSV-2.
“Heterosexual intercourse is usually not very efficient for transmitting HIV, but the efficiency of heterosexual transmission nearly triples in the presence of herpes simplex virus type 2,” notes the study’s lead author, Don Des Jarlais, PhD, Deputy Director, Research Methods and Infectious Diseases Cores, Center for Drug Use and HIV Research (CDUHR) and Professor of Psychiatry and of Preventive Medicine at Mount Sinai Beth Israel. “In New York City, we have done an excellent job of reducing HIV among persons who inject drugs and we must now put more efforts into reducing sexual transmission associated with non-injecting drug use.”
The study concludes that an increase in HIV infection among these non-injecting drug users is better considered as an increase in HSV- 2/HIV co-infection rather than simply an increase in HIV prevalence. Additional interventions (such as treatment as prevention and pre-exposure prophylaxis) are needed to reduce further HIV transmission from HSV-2/HIV co-infected non-injecting drug users.
The City Department of Health and Mental Hygiene has initiated a program “treatment as prevention,” in which HIV infected persons are given anti-viral medications to both protect their own health and to reduce the chances that they will transmit HIV to others. There are also new federal recommendations to provide anti-retroviral medications to HIV uninfected persons at high risk for becoming infected.
“If we can implement these programs on a large scale, we should be able to control sexual transmission of HIV in the city, and achieve the goal of an “End to the AIDS Epidemic,” said Dr. Des Jarlais.
Authors and affiliations: Don C. Des Jarlais, Kamyar Arasteh, Courtney McKnight, David C. Perlman, and Jonathan Feelemyer: The Baron Edmond de Rothschild Chemical Dependency Institute, Beth Israel Medical Center, New York, New York, United States of America; Holly Hagan, College of Nursing, New York University, New York, New York, United States of America; Hannah L. F. Cooper, Rollins School of Public Health, Emory University, Atlanta, Georgia, United States of America.
Funding: This work received support from the National Institutes of Health (NIH)under NIH Grant# 5 R01 DA 03574. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
The mission of CDUHR is to end the HIV and HCV epidemics in drug using populations and their communities by conducting transdisciplinary research and disseminating its findings to inform programmatic, policy, and grass roots initiatives at the local, state, national, and global levels. The Center is dedicated to increasing the understanding of the substance use-HIV/AIDS epidemic, particularly among individuals in high-risk contexts. The Center's theme is "Discovery to Implementation & Back: Research Translation for the HIV/Substance Use Epidemic."
About the Mount Sinai Health System
The Mount Sinai Health System is an integrated health system committed to providing distinguished care, conducting transformative research, and advancing biomedical education. Structured around seven member hospital campuses and a single medical school, the Health System has an extensive ambulatory network and a range of inpatient and outpatient services—from community-based facilities to tertiary and quaternary care.
The System includes approximately 6,600 primary and specialty care physicians, 12-minority-owned free-standing ambulatory surgery centers, over 45 ambulatory practices throughout the five boroughs of New York City, Westchester, and Long Island, as well as 31 affiliated community health centers. Physicians are affiliated with the Icahn School of Medicine at Mount Sinai, which is ranked among the top 20 medical schools both in National Institutes of Health funding and by U.S. News & World Report. For more information, visit http://www.mountsinai.org/
About New York University College of Nursing
NYU College of Nursing is a global leader in nursing education, research, and practice. It offers a Bachelor of Science in Nursing, a Master of Science and Post-Master’s Certificate Programs, a Doctor of Philosophy in Research Theory and Development, and a Doctor of Nursing Practice degree. For more information, visit nursing.nyu.edu
Type: Press Release
Press Contact: Christopher James | (212) 998-6876